Catalyst overview
Research summary
This catalyst tracks a Phase 1b update for ATR12-351 (ATR-12) in Netherton syndrome. The expected timing is based on the latest available company guidance and may change.
8/28/24- First patient dosed. 6/17/25- Reported initial safety data. 8/11/25- Topline data in Q1 2026. 11/12/25:- Company continues Phase 1b ATR-12 trial in Netherton syndrome; initial safety and topline data planned. 02/27/26:- Phase 1b ATR-12 shows promising safety; topline data timing updated to H2 2026. 05/13/26:- Topline Ph1b ATR-12 Netherton data still anticipated H2 2026. 08/12/26:- Further Ph1b enrollment is strategically paused. Future ATR-12 data timing is TBA.
Verification
Confirm timing and program details against the company announcement or filing.